DDInter129 DDInter1376
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Atazanavir {u} (Compound) binds {v} (Gene) ABCB1
Atazanavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Atazanavir {u} (Compound) causes {v} (Side Effect) Pelvic pain
Atazanavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Abiraterone
Atazanavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Caffeine
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Methylprednisolone
Atazanavir (Compound) resembles Ritonavir (Compound)
Atazanavir (Compound) binds ABCB1 (Gene)
Atazanavir (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Atazanavir (Compound) causes Pelvic pain (Side Effect)
Atazanavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Atazanavir may cause a minor interaction that can limit clinical effects when taken with Caffeine
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene
Atazanavir may lead to a major life threatening interaction when taken with Venetoclax
Atazanavir may lead to a major life threatening interaction when taken with Methylprednisolone